


ETCTN Trials by Disease/Treatment Area: Leukemia



NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide.

ETCTN Leukemia Trials (Open as of 3/10/2025)

Protocol Number	Phase	Protocol Title
10273	I	A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia
10335	I	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
10237	I	A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
10538	II	Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
10596	Ib	A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease
10637	II	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia
10653	I	A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML
10630	I	Phase 1 Trial of ladademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML
10674	I	A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
10675	II	A Randomized Phase II Trial of ASTX727 +/- ladademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
10664	Ib/II	Phase 1b/2 Study of Combination Tovorafenib and Rituximab Treatment in Classical Hairy Cell Leukemia
10695	I	Lintuzumab-Ac225 monotherapy for patients with hypomethylating agent-refractory myelodysplastic syndrome
10708	Pilot	A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia